Compare Suncor Energy Inc. (SU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs TG Therapeutics Inc — how do they compare? Suncor Energy Inc. trades at $63.65 (market cap $72.86B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Suncor Energy Inc. is far larger — about 8.8× TG Therapeutics Inc's market cap, and Suncor Energy Inc. pays a 2.71% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SU | TGTX | |
|---|---|---|
Market Cap | $72.86B | $8.26B |
Sector | Energy | Health |
52-Week High | $69.73 | $59.06 |
52-Week Low | $38.17 | $26.39 |
Enterprise Value | $80.99B | $8.50B |
Dividend Yield | 2.71% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
